Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Products under Development by Stage of Development | 8 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Products under Development by Therapy Area | 9 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Products under Development by Indication | 10 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Products under Development by Companies | 13 | 2 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Companies Involved in Therapeutics Development | 21 | 4 |
| Bioprojet SCR | 21 | 1 |
| Novartis AG | 22 | 1 |
| Pharmaleads SA | 23 | 1 |
| Theravance Biopharma, Inc. | 24 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Drug Profiles | 25 | 14 |
| (sacubitril + valsartan) Drug Profile | 25 | 5 |
| dexecadotril Drug Profile | 30 | 1 |
| PL-265 Drug Profile | 31 | 1 |
| PL-37 Drug Profile | 32 | 2 |
| STR-324 Drug Profile | 34 | 2 |
| TD-0714 Drug Profile | 36 | 2 |
| TD-1439 Drug Profile | 38 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Dormant Projects | 39 | 2 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Discontinued Products | 41 | 1 |
| Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Featured News &Press Releases | 42 | 14 |
| Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients | 42 | 1 |
| Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology | 43 | 1 |
| Jun 09, 2016: New Review of PARADIGM-HF Results: LCZ696, an Angiotensin-neprilysin Inhibitor, Versus Enalapril in Heart Failure | 44 | 1 |
| May 21, 2016: Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals | 44 | 1 |
| May 19, 2016: Novartis announces investment in FortiHFy clinical program of Entresto and heart failure | 45 | 1 |
| Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition | 46 | 1 |
| Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless | 47 | 1 |
| Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin | 47 | 2 |
| Jan 20, 2016: Breakthrough drug for heart failure now available in the UK | 49 | 1 |
| Dec 08, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin | 49 | 1 |
| Dec 02, 2015: New heart failure therapy projected to increase life expectancy | 50 | 1 |
| Nov 24, 2015: Novartis' heart failure medicine Entresto receives EU approval | 51 | 1 |
| Nov 10, 2015: Novartis heart failure medicine Entresto substantially cuts 30-day hospital readmissions, new post-hoc analysis shows | 52 | 1 |
| Oct 13, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-0714, an Inhibitor of Neprilysin | 53 | 1 |
| Oct 06, 2015: Heart failure treatment ENTRESTO (LCZ696) shown to reduce the risk of cardiovascular death and hospitalization approved by Health Canada | 54 | 2 |
| Appendix | 56 | 2 |
| Methodology | 56 | 1 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 56 | 1 |
| Expert Panel Validation | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 57 | 1 |
